HC Wainwright Has Positive Outlook for XOMA FY2025 Earnings

XOMA Co. (NASDAQ:XOMA) – Equities research analysts at HC Wainwright raised their FY2025 earnings per share estimates for XOMA in a note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $0.17 for the year, up from their previous estimate of $0.15. HC Wainwright has a “Buy” rating and a $117.00 price target on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for XOMA’s FY2026 earnings at $0.64 EPS.

Separately, StockNews.com upgraded shares of XOMA from a “sell” rating to a “hold” rating in a report on Wednesday, August 14th.

XOMA Stock Up 0.6 %

XOMA stock opened at $31.16 on Monday. The company has a market capitalization of $364.70 million, a price-to-earnings ratio of -8.95 and a beta of 0.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 8.71 and a current ratio of 8.71. The business’s 50 day moving average price is $28.53 and its two-hundred day moving average price is $26.78. XOMA has a fifty-two week low of $14.33 and a fifty-two week high of $33.78.

XOMA (NASDAQ:XOMA) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.02). XOMA had a negative return on equity of 24.57% and a negative net margin of 151.34%. The company had revenue of $11.09 million during the quarter, compared to analysts’ expectations of $8.37 million.

Hedge Funds Weigh In On XOMA

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ellsworth Advisors LLC purchased a new stake in XOMA in the third quarter worth approximately $516,000. Rhumbline Advisers boosted its stake in shares of XOMA by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after buying an additional 1,334 shares during the last quarter. Bank of New York Mellon Corp increased its position in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after acquiring an additional 1,968 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in XOMA in the first quarter valued at about $212,000. Finally, BNP Paribas Financial Markets boosted its position in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,266 shares during the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.